Related Experiment Video
Updated: Jul 15, 2025

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019
Progressive multifocal leukoencephalopathy without overt immunosuppression
Varun Jain1, Hannah Branstetter1, Srikar Savaram1
1Department of Neurology, College of Medicine, University of Florida, Gainesville, FL.
Abstract:
Progressive multifocal leukoencephalopathy (PML) is a central nervous system disease caused by the human polyomavirus 2 that usually occurs in a setting of immunodeficiency. PML without overt immunosuppression is considered a rare occurrence but has been described in multiple previous case reports and series. Its prevalence, overall frequency, and prognosis are largely unknown. This is a single-center retrospective review of all University of Florida cases with the ICD10 PML diagnosis code (A81.2). PML without overt immunosuppression was defined as absence of human immunodeficiency virus (HIV) infection, hematological malignancy, immunomodulatory/-suppressive medications, autoimmune conditions with a propensity for PML (sarcoidosis, systemic lupus erythematosus). Cases that did not fulfill criteria for clinically or histologically definite PML were excluded. Of 52 patients with the ICD10 code A 81.2, 17 fulfilled definite diagnostic criteria for PML. Overt immunosuppression was identified in 15/17 (88.2%) cases (10/17 (58.8%): human immunodeficiency virus; 5/17 (29.4%): immunomodulatory/-suppressive medication). Two/seventeen (11.8%) cases were consistent with PML without overt immunosuppression. Possible contributing factors were a preceding dog bite and mild hypogammaglobulinemia M (39 mg/dL) in case 1 and significant alcohol use without evidence for liver disease in case 2. Both cases were fatal within 6 (case 1) and 2 (case 2) months. The results suggest that PML without overt immunosuppression may be more common than previously described. Therefore, PML should be considered even in the absence of overt immunosuppression if clinical and radiographic findings are suggestive of the diagnosis.
Insights
Progressive multifocal leukoencephalopathy (PML) can occur without obvious immunosuppression, challenging its rarity. This study found PML in 11.8% of cases without overt immunosuppression, suggesting it may be more common than previously thought.
Area of Science:
- Neurology
- Infectious Diseases
- Immunology
Background:
- Progressive multifocal leukoencephalopathy (PML) is a rare, severe central nervous system disease.
- PML is typically associated with significant immunodeficiency.
- The occurrence and characteristics of PML in individuals without overt immunosuppression are not well-defined.
Purpose of the Study:
- To investigate the prevalence and characteristics of PML cases occurring in the absence of overt immunosuppression.
- To determine if PML without overt immunosuppression is more common than previously reported.
Main Methods:
- Retrospective review of patients diagnosed with PML (ICD10 code A81.2) at a single center.
- Defined PML without overt immunosuppression by excluding HIV, hematological malignancy, immunosuppressive medications, and specific autoimmune conditions.
- Included only cases with definite clinical or histological PML diagnosis.
Main Results:
- Out of 52 patients with the PML diagnosis code, 17 met definite PML criteria.
- Overt immunosuppression was present in 15 of 17 (88.2%) cases, primarily due to HIV or immunosuppressive medications.
- Two of 17 (11.8%) cases presented with PML without overt immunosuppression, with potential contributing factors including a dog bite with hypogammaglobulinemia and significant alcohol use.
Conclusions:
- PML without overt immunosuppression may occur more frequently than previously recognized.
- The diagnosis of PML should be considered even in patients without apparent immunosuppression if clinical and radiographic findings are suggestive.
- Both identified cases without overt immunosuppression were fatal, highlighting the severity of the condition.

